Physicians' Academy for Cardiovascular Education

How does Lipid Lowering Prevent the Clinical Manifestations of CV Disease

Slides (presentation) - Jan. 14, 2011

How does Lipid Lowering Prevent the Clinical Manifestations of CV Disease

John J.P. Kastelein, MD PhD
Academic Medical Center / University of Amsterdam
Dept. Vascular Medicine
Amsterdam, The Netherlands
Dubai - january 2011




Click on slides to view presentation


How does Lipid Lowering Prevent the Clinical Manifestations of CV Disease?
Mortality from IHD
Mortality from Ischemic Heart Disease and Cholesterol 3,020 Deaths
Discovery of statins
Discovery of statins
Clear Cardiovascular Benefits
Clear Cardiovascular Benefits of Intensive Lipid-Lowering Therapy
Deaths Due to
Deaths Due to Suicide, Cancer, and Hemorrhagic Stroke
Cardiovascular events occurred in 22 (10%) of 227 patients with abnormal liver tests who received statin (3·2 events per 100 patient-years) and 63 (30%) of 210 patients with abnormal liver tests who did not receivestatin (10·0 events per 100 patient-years; 68% relative risk reduction, p<0·0001). This cardiovascular disease benefit was greater (p=0·0074) than it was in patients with normal liver tests
GREACE:
GREACE: Enzyme Activity in Patients with Raised Liver Enzymes. A) On Statins B) Not On Statins

Download presentation

Share this page with your colleagues and friends: